Heart Failure in Newly Diagnosed Atrial Fibrillation: GLORIA-AF Phase III Insights
Overview
In the GLORIA-AF Phase III registry of 21,125 patients with recent atrial fibrillation (AF), 21.9% had congestive heart failure (CHF). CHF presence, especially with left ventricular ejection fraction (LVEF) ≤ 40%, was linked to different oral anticoagulant use patterns and a doubled risk of death and major cardiovascular events over 3 years.
Background
Atrial fibrillation and congestive heart failure are common chronic conditions that frequently coexist due to shared risk factors such as hypertension and coronary artery disease. The prevalence of AF in heart failure patients varies widely, influenced by heart failure severity and LVEF phenotype. CHF is a recognized stroke risk factor in AF, influencing anticoagulation decisions. Despite existing knowledge, real-world data on how CHF impacts AF management and outcomes remain limited.
Data Highlights
Parameter
Value
Total patients enrolled
21,125
Patients with CHF
4,632 (21.9%)
Mean age
70.2 ± 10.3 years
Female patients
44.9%
Odds ratio for OAC use in CHF with LVEF ≤ 40%
1.47 (95% CI: 1.27–1.71)
Hazard ratio for primary outcome with CHF
2.04 (95% CI: 1.87–2.23)
Key Findings
CHF was present in approximately one in five patients with newly diagnosed AF.
Patients with CHF and reduced LVEF (≤ 40%) had higher odds of receiving oral anticoagulants compared to those without CHF.
Non-vitamin K oral anticoagulants were less frequently used in CHF patients regardless of LVEF status.
CHF was independently associated with a twofold increase in risk of all-cause death and major adverse cardiovascular events over 3 years.
The increased risk of adverse outcomes was more pronounced in patients with LVEF ≤ 40%.
CHF patients exhibited a more complex clinical profile and different management patterns compared to non-CHF AF patients.
Clinical Implications
Clinicians should recognize that CHF is common in patients with recent AF diagnosis and significantly impacts prognosis and treatment strategies. Careful assessment of LVEF can guide anticoagulation choices, as patients with reduced LVEF may benefit from more aggressive oral anticoagulant use. Enhanced monitoring and tailored interventions are warranted to improve outcomes in this high-risk subgroup.
Conclusion
CHF frequently coexists with AF and is associated with distinct management approaches and worse clinical outcomes, particularly in patients with reduced LVEF. These findings underscore the need for optimized therapeutic strategies to improve prognosis in AF patients with heart failure.
References
Romiti et al. 2025 -- Heart Failure Among Patients Recently Diagnosed with Atrial Fibrillation: Insights from the GLORIA-AF Phase III Registry
by Bernadette Corica, Giulio Francesco Romiti, Marco Proietti, Giuseppe Boriani, Brian Olshansky, Menno V Huisman, Gregory Y H Lip, on behalf of the GLORIA-AF Investigators
